Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026)
Johnson & Johnson (JNJ) posted Cash & Current Investments of $20.8 billion for Q2 2026, down 5.86% sequentially from $22.1 billion in Q1 2026, and up 9.95% YoY from $18.9 billion in Q2 2025.
Johnson & Johnson (JNJ) Cash & Current Investments (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Cash & Current Investments for 18 years, with the latest figure at $20.8 billion in Q2 2026.
- Quarterly Cash & Current Investments rose 9.95% year-over-year to $20.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $20.8 billion (up 9.95% YoY) and the FY2025 annual result came in at $20.1 billion, down 18.02% from the prior year.
- Cash & Current Investments declined to $20.8 billion in Q2 2026 per JNJ's latest filing, from $22.1 billion in the prior quarter.
- Over five years, Cash & Current Investments peaked at $38.8 billion in Q1 2025 and troughed at $18.6 billion in Q3 2025.
- A 5-year average of $25.6 billion and a median of $24.5 billion in 2024 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2025 and 2026: Cash & Current Investments soared 47.92% in 2025, then tumbled 43.14% in 2026.
- Over 5 years, Cash & Current Investments stood at $34.1 billion in 2022, then sank by 32.72% to $22.9 billion in 2023, then climbed by 6.96% to $24.5 billion in 2024, then decreased by 18.02% to $20.1 billion in 2025, then advanced by 3.26% to $20.8 billion in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $20.8 billion, $22.1 billion, and $20.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 20.76 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 7.14 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 7.69 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.18 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 4.17 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 7.38 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 20.76 Bn |
| Mar 29, 2026 | 22.05 Bn |
| Dec 28, 2025 | 20.10 Bn |
| Sep 28, 2025 | 18.56 Bn |
| Jun 29, 2025 | 18.88 Bn |
| Mar 30, 2025 | 38.78 Bn |
| Dec 29, 2024 | 24.52 Bn |
| Sep 29, 2024 | 20.30 Bn |
| Jun 30, 2024 | 25.48 Bn |
| Mar 31, 2024 | 26.22 Bn |
| Dec 31, 2023 | 22.93 Bn |
| Oct 1, 2023 | 23.51 Bn |
| Jul 2, 2023 | 28.51 Bn |
| Apr 2, 2023 | 24.61 Bn |
| Jan 1, 2023 | 22.28 Bn |
| Oct 2, 2022 | 34.08 Bn |
| Jul 3, 2022 | 32.57 Bn |
| Apr 3, 2022 | 30.39 Bn |
| Jan 2, 2022 | 31.61 Bn |
| Oct 3, 2021 | 31.00 Bn |